Comparison · NCT01648023-deaths
Randomization to LC OR ONCOZENE Bead With Gem-Cis or Gem-Carbo vs Randomization to Gem-Cis or Gem-Carbo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Randomization to LC OR ONCOZENE Bead With Gem-Cis or Gem-Carbo vs Randomization to Gem-Cis or Gem-Carbo: deaths from any cause. Trial comparisons, record NCT01648023-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01648023-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.708 | 0.508 | 0.851 | wilson | |
| Risk in group 2 | 0.727 | 0.518 | 0.868 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0189 | -0.264 | 0.234 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.974 | 0.678 | 1.4 | log | |
| Odds ratio, group 1 over group 2 | 0.911 | 0.252 | 3.3 | log | |
| Number needed to treat, for one fewer death from any cause on Randomization to LC OR ONCOZENE Bead With Gem-Cis or Gem-Carbo than on Randomization to Gem-Cis or Gem-Carbo | 52.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Randomization to LC OR ONCOZENE Bead With Gem-Cis or Gem-Carbo | Transarterial Chemoembolization (LC or ONCOZENE Bead) with Gem-Cis or Gem-Carbo~LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo | 17 | 24 | EG000 |
| Group 2 | Randomization to Gem-Cis or Gem-Carbo | Gem-Cis or Gem-Carbo alone~Gem-Cis or Gem-Carbo | 16 | 22 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse and Serious Adverse Events were assessed for 15 months. All-Cause Morality was assessed from randomization to Date of Death from Any Cause (up to 55 months)
Source ClinicalTrials.gov
Trial
- Title
- Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
- NCT number
- NCT01648023
- Phases
- PHASE2
- Conditions
- Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo, Gem-Cis or Gem-Carbo
- Lead sponsor
- Robert C. Martin
- Results first posted
- 2022-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01648023?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01648023-deaths